Company news
Avacta Group PLC news in 2022
Avacta Group PLC's news releases, calls and decks from 2022, newest first.
Avacta to Host Therapeutics Division Science Day
December 19, 2022
Result of the Open Offer
November 8, 2022
Avacta to Present at Theranostics FAP Summit
October 31, 2022
Admission of the Company's Ordinary Shares
October 20, 2022
Posting of the Company's Open Offer Circular
October 20, 2022
Private CB and ABB Launch
October 18, 2022
Proposed acquisition of Launch Diagnostics
October 18, 2022
Interim Results for the Period Ended 30 June 2022
September 29, 2022
AVA6000 receives Orphan Drug Designation from FDA
September 5, 2022
Phase I study of AVA6000 advances to fourth cohort
September 1, 2022
AffyXell successfully completes funding round
July 21, 2022
LG Chem renews license triggers payment to Avacta
June 30, 2022
Second dose escalation in phase 1 trial of AVA6000
June 29, 2022
AffyXell expands partnership with GenScript ProBio
May 16, 2022
London Therapeutics headquarters established
May 11, 2022
Block Listing Application to AIM (update)
May 6, 2022
AffyXell milestone and increased equity stake
April 13, 2022
Poster presented at the AACR available to download
April 12, 2022
AffyXell partners with Biocytogen and KNTSC
April 8, 2022
AVA6000 data poster presentation at AACR
March 29, 2022
Directorate Change
March 21, 2022
Vimian acquires Avacta's Animal Health Division
March 16, 2022
Dose escalation in the phase I trial of AVA6000
February 3, 2022
Second pre|CISION Pro-drug Candidate Selected
January 18, 2022
Update on AffiDX and detection of Omicron variant
January 10, 2022
Calls in 2022
Decks in 2022
- FY2021 Earnings Presentation
Earnings · 28 slides · Apr 6, 2022